MilliporeSigma
All Photos(1)

Documents

A0357000

Alprazolam

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing

Synonym(s):
8-Chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
Empirical Formula (Hill Notation):
C17H13ClN4
CAS Number:
Molecular Weight:
308.76
MDL number:
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

alprazolam

manufacturer/tradename

EDQM

drug control

regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Cc1nnc2CN=C(c3ccccc3)c4cc(Cl)ccc4-n12

InChI

1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3

InChI key

VREFGVBLTWBCJP-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
L0750500C1500000O0225000
Alprazolam European Pharmacopoeia (EP) Reference Standard

A0357000

Alprazolam

Lorazepam European Pharmacopoeia (EP) Reference Standard

L0750500

Lorazepam

Chlordiazepoxide hydrochloride European Pharmacopoeia (EP) Reference Standard

C1500000

Chlordiazepoxide hydrochloride

Oxazepam European Pharmacopoeia (EP) Reference Standard

O0225000

Oxazepam

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

format

neat

format

neat

format

neat

format

neat

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

API family

alprazolam

API family

lorazepam

API family

chlordiazepoxide

API family

oxazepam

drug control

regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

drug control

regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

drug control

-

drug control

regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Alprazolam EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

Product numbers are combined with Pack Sizes/Quantity when displayed on the website (example: T1503-25G). Please make sure you enter ONLY the product number in the Product Number field (example: T1503).

Example:

T1503
Product Number
-
25G
Pack Size/Quantity

Additional examples:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

enter as 1.000309185)

Having trouble? Feel free to contact Technical Service for assistance.

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich Products

  • For a lot number such as TO09019TO, enter it as 09019TO (without the first two letters 'TO').

  • For a lot number with a filling-code such as 05427ES-021, enter it as 05427ES (without the filling-code '-021').

  • For a lot number with a filling-code such as STBB0728K9, enter it as STBB0728 without the filling-code 'K9'.

Not Finding What You Are Looking For?

In some cases, a COA may not be available online. If your search was unable to find the COA you can request one.

Request COA

Customers Also Viewed

Slide 1 of 7

1 of 7

Alprazolam-d5 solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

A-910

Alprazolam-d5 solution

Bromazepam European Pharmacopoeia (EP) Reference Standard

B1143000

Bromazepam

Lorazepam United States Pharmacopeia (USP) Reference Standard

USP

1370305

Lorazepam

Diazepam United States Pharmacopeia (USP) Reference Standard

USP

1185008

Diazepam

Diazepam

Sigma-Aldrich

D0899

Diazepam

(±)-Lorazepam

Sigma-Aldrich

L1764

(±)-Lorazepam

Weam Elbezanti et al.
Viruses, 12(2) (2020-02-14)
Antiretroviral therapy (ART) lowers human immunodeficiency virus type 1 (HIV-1) viral load to undetectable levels, but does not eliminate the latent reservoir. One of the factors controlling the latent reservoir is transcriptional silencing of the integrated HIV-1 long terminal repeat
Dean T Acheson et al.
Human psychopharmacology, 27(4), 419-427 (2012-07-12)
Heightened anticipation of future events has been characterized as a feature of certain anxiety disorders. In functional magnetic resonance imaging studies, anticipation of fearful/threatening images has been shown to robustly activate the insular cortex and amygdala in healthy subjects, in
J M Jonas et al.
The Journal of clinical psychiatry, 54 Suppl, 25-45 (1993-10-01)
A review of the worldwide published literature was conducted to assess the efficacy and safety of alprazolam for the treatment of anxiety disorders, panic disorder, and depression in comparison with those of other active drugs (including other benzodiazepines and antidepressant
J O Cole et al.
The Journal of clinical psychiatry, 54 Suppl, 49-61 (1993-10-01)
A review of the published case reports of adverse behavioral episodes or unexpected psychopathology in patients taking benzodiazepines was undertaken in an attempt to determine if these adverse or unexpected events are more likely to occur with alprazolam when compared
E M Sellers et al.
The Journal of clinical psychiatry, 54 Suppl, 64-75 (1993-10-01)
The incidence of nonmedical use of alprazolam is very low relative to its widespread legitimate medical use; in fact, given the millions of patients who have received this medication, the incidence is remarkably small. In particular, among patients with anxiety

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service